We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$1.65M
Cap. Flow
+$718
Cap. Flow %
0%
Top 10 Hldgs %
60.41%
Holding
141
New
23
Increased
22
Reduced
12
Closed
32

Top Buys

Rank Stock Value
1
INMB icon
INmune Bio
INMB
+$5.31M
2
STAA icon
STAAR Surgical
STAA
+$5.12M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$2.44M
4
NVNO
enVVeno Medical
NVNO
+$1.94M
5
CVX icon
Chevron
CVX
+$1.6M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.85M
2
U icon
Unity
U
+$3.33M
3
SKIN icon
SkinHealth Systems
SKIN
+$2.9M
4
FFIV icon
F5
FFIV
+$2.71M
5
NVAX icon
Novavax
NVAX
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 78.61%
2 Financials 5.86%
3 Technology 3.93%
4 Communication Services 3.41%
5 Consumer Discretionary 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMZN icon
26
Amazon
AMZN
$2.94T
$1.64M 0.85%
10,000
+6,000
+150% +$1.03M
GDRX icon
27
GoodRx Holdings
GDRX
$1.11B
$1.64M 0.85%
+40,000
New +$1.45M
CVX icon
28
Chevron
CVX
$371B
$1.62M 0.84%
+16,000
New +$1.6M
MTTR
29
DELISTED
Matterport, Inc. Class A Common Stock
MTTR
$1.56M 0.81%
82,500
-16,500
-17% -$268K
BTAI icon
30
BioXcel Therapeutics
BTAI
$26M
$1.52M 0.79%
3,125
+500
+19% +$220K
ONCT
31
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.5M 0.78%
18,000
– –
SURF
32
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.29M 0.67%
170,500
– –
AVXL icon
33
Anavex Life Sciences
AVXL
$297M
$1.26M 0.66%
+70,500
New +$1.4M
IMDX
34
Insight Molecular Diagnostics
IMDX
$161M
$1.18M 0.61%
16,500
– –
EIGR
35
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.06M 0.55%
5,283
– –
HSDT icon
36
Solana Company
HSDT
$100M
$1.02M 0.53%
2
– –
MDNA
37
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$970K 0.5%
350,000
– –
KPLT icon
38
Katapult Holdings
KPLT
$30.2M
$950K 0.49%
+7,000
New +$1.22M
PDSB icon
39
PDS Biotechnology
PDSB
$40.6M
$894K 0.46%
60,000
+15,000
+33% +$187K
XEC
40
DELISTED
CIMAREX ENERGY CO
XEC
$872K 0.45%
+10,000
New +$694K
IMTX icon
41
Immatics
IMTX
$1.34B
$826K 0.43%
63,500
– –
ENLV icon
42
Enlivex Ltd
ENLV
$36.7M
$815K 0.42%
5,500
– –
GRTS
43
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$799K 0.41%
+74,000
New +$673K
ZETA icon
44
Zeta Global
ZETA
$6.75B
$791K 0.41%
+135,000
New +$861K
HLMN icon
45
Hillman Solutions
HLMN
$1.81B
$775K 0.4%
65,000
+32,500
+100% +$398K
MRKR icon
46
Marker Therapeutics
MRKR
$19M
$743K 0.39%
43,940
+1,940
+5% +$39.7K
SLV icon
47
iShares Silver Trust
SLV
$29.9B
$739K 0.38%
36,000
– –
CRDF icon
48
Cardiff Oncology
CRDF
$74.3M
$683K 0.35%
102,500
– –
COIN icon
49
Coinbase
COIN
$39.5B
$682K 0.35%
3,000
+300
+11% +$73.8K
ABTC
50
American Bitcoin Corp
ABTC
$477M
$654K 0.34%
+8
New +$817K
1
2
3 4 5

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, ACT Capital Management held 141 positions worth $193M, down 0.85% from $195M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

ACT Capital Management's Q3 2021 filing shows 23 new, 22 increased, 12 reduced and 32 closed positions. Its largest new stake was INmune Bio: 275,000 shares worth $5.34M. The largest sale was Filana Therapeutics, an estimated $3.85M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials and Technology.

  • ACT Capital Management's largest Q3 2021 buy was INmune Bio: 275,000 shares worth $5.34M.
  • ACT Capital Management added most to STAAR Surgical in Q3 2021, an estimated $5.12M increase.
  • ACT Capital Management's biggest Q3 2021 reduction was Unity, cutting an estimated $3.33M.
  • ACT Capital Management fully exited Filana Therapeutics in Q3 2021, selling an estimated $3.85M.
  • ACT Capital Management's ten largest holdings make up 60% of its $193M portfolio in Q3 2021.
  • ACT Capital Management opened 23 new positions and closed 32 in Q3 2021.
  • ACT Capital Management's portfolio value fell 0.85% quarter-over-quarter to $193M.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.